Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
Yen-Shen LuSeock-Ah ImMarco ColleoniFabio FrankeAditya BardiaFatima CardosoNadia HarbeckSara HurvitzLouis ChowJoohyuk SohnKeun Seok LeeSaul Campos-GomezRafael Villanueva VazquezKyung Hae JungK Govind BabuPaul Wheatley-PriceMichelino De LaurentiisYoung-Hyuck ImSherko KuemmelNagi S El SaghirRuth O'ReganClaudia GaschNadia SolovieffCraig WangYongyu WangArunava ChakravarttyYan JiDebasish TripathyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Ribociclib plus ET continued to show significantly longer OS than ET alone in pre-/perimenopausal patients, including patients aged less than 40 years, with HR+/HER2- ABC with 53.5 months of median follow-up (ClinicalTrials.gov, NCT02278120).